Overview of melanoma vaccines: Active specific immunotherapy for melanoma patients

Seminars in Surgical Oncology

Volumn 14, Issue 4, 1998, Pages 328-336

  Ollila, David W ^a   Kelley, Mark C ^a   Gammon, Guy ^a   Morton, Donald L ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

Cancer vaccines; Cellular immunity; Clinical trials; Combined antineoplastic agents; Dendritic cells; Gangliosides; IgG; IgM; Immunology; Immunotherapy; Interferons; Melanoma; Neoplasm antigens; Neoplasm staging; Survival analysis; Survival rate

Indexed keywords

ALPHA2B INTERFERON; B7 ANTIGEN; BCG VACCINE; CARMUSTINE; CISPLATIN; DACARBAZINE; GANGLIOSIDE GM2; IMMUNOLOGICAL ADJUVANT; KEYHOLE LIMPET HEMOCYANIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELACINE; MELANOMA ANTIGEN; MELANOMA VACCINE; PHOSPHORYL LIPID A; QS 21; TAMOXIFEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VACCINIA ONCOLYSATE;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CLINICAL TRIAL; HEADACHE; HUMAN; HUMORAL IMMUNITY; INTRADERMAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LYMPHADENECTOMY; MELANOMA; NAUSEA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

CANCER VACCINES; HUMANS; IMMUNOTHERAPY, ACTIVE; MELANOMA; SKIN NEOPLASMS;

EID: 0031897895     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2388(199806)14:4<328::AID-SSU9>3.0.CO;2-4     Document Type: Review

References (72)

1. Koh HK: Cutaneous melanoma. N Engl J Med 1991; 325:171-182.
2. American Cancer Society. "Cancer facts and figures, 1997." Atlanta: American Cancer Society; 1997, p. 4.
3. Legha SS, Ring S, Papadopoulos N, et al.: A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, dacarbazine (CVD) for metastastic melanoma. Cancer 1989; 64:2024-2029.
4. McClay EF, Mastrangelo MJ, Berd D, Bellet RE: Effective combination chemo/hormonal therapy for malignant melanoma: experience with three consecutive trials. Int J Cancer 1992; 50:553-556.
5. Legha SS, Ring S, Bedikian A, et al.: Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. Ann Oncol 1996; 7:827-835.
6. O'Day SJ, Boasberg P, Guo M, et al.: Phase II trial of concurrent biochemotherapy (c-BC) with decrescendo interleukin-2 (d-IL-2), tamoxifen (T), and G-CSF support in patients with metastatic melanoma (MM) [Abstract]. Proc Am Soc Clin Oncol 1997; 16:490a.
7. Kirkwood JM, Strawderman MH, Ernstoff MS, et al.: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14:7-17.
8. Morton DL, Malmgren RA, Holmes EC, Ketcham AS. Demonstration of antibodies against malignant melanoma by immunofluorescence. Surgery 1968; 64:233-240.
9. Morton DL, Eilber FR, Malmgren RA, et al.: Immunological factors which influence responses to immunotherapy in malignant melanoma. Surgery 1970; 68:158-164.
10. Mukherji B, Chakraborty NG, Sivanandham M: T-cell clones that react against autologous human tumors [Review]. Immunol Rev 1990; 116:33-62.
11. Morton DL, Wanek L, Nizze JA, et al.: Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Ann Surg 1991; 214:491-501.
12. Nauts HC: A review of the influence of bacterial infection and of bacterial products (Coley's toxin) on malignant tumors in man. Acta Med Scand Suppl 1953; 276:1-103.
13. Czarnetzki BM, Macher E, Suciu S, et al.: Long-term adjuvant immunotherapy in stage I high risk malignant melanoma, comparing two BCG preparations vs. non-treatment m a randomised multicentre study (EORTC Protocol 18781). Eur J Cancer 1993; 29A:1237-1242.
14. Morton DL, Barth A: Vaccine therapy for malignant melanoma [Review]. CA Cancer J Clin 1996; 46:225-244.
15. Ravindranath MH, Morton DL: Active specific immunotherapy with vaccines. In Holland JF, Frei E, Bast R, et al. (eds): "Cancer medicine." 4th ed. Baltimore: Williams and Wilkins; 1997. p. 1179-1198.
16. Brichard V, Van Pel A, Wolfel T, et al.: The tyrosinase gene encodes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993; 178:489-495.
17. Kwon BS: Pigmentation genes: the tyrosinase gene family and the p-mel 17 gene family. J Invest Dermatol 1993, 100(2 Suppl):134S-140S.
18. Adema GJ, de Boer AJ, Vogel AM, et al.: Molecular characterization of melanocyte lineage-specific antigen gp100. J Biol Chem 1994; 269:20126-20133.
19. Vijayasaradhi S, Bouchard B, Houghton AN: The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product. J Exp Med 1990; 171:1375-1380.
20. Traversari C, van der Bruggen P, Luescher IF, et al.: A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 1992; 176:1453-1457.
21. Gaugler B, Van den Eynde B, van der Bruggen P, et al.: Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 1994; 179:921-930.
22. Boel P, Wildmann C, Sensi ML, et al.: BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 1995; 2:167-175.
23. Stretch JR, Gatler KC, Ralfkier E, et al.: Expression of mutant p53 in melanoma. Cancer Res 1991; 253:49-53.
24. Relyveld EH, Ben-Efraim S: Preparation of vaccines by the action of glutaraldehyde on toxins, bacteria, viruses, allergens and cells. Methods Enzymol 1983; 93:24-60.
25. Seigler HF, Cox E, Mutzner F: Specific active immunotherapy for melanoma. Ann Surg 1978; 100:366-372.
26. Tao MH, Levy R: Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 1993; 362:755-758.
27. Berd D, Mastrangelo MJ: Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide. Cancer Invest 1988; 6:337-349.
28. Peters LC, Brandhorst JS, Hanna MG Jr: Preparation of immunotherapeutic autologous tumor cell vaccines from solid tumors. Cancer Res 1979; 39:1353-1360.
29. Berd D, MacGuire HC, McCue P, et al.: Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients. J Clin Oncol 1990; 8:1858-1867.
30. Stingl G, Brocker EB, Mertelsmann R, et al.: Phase I study to the immunotherapy of metastatic malignant melanoma by a cancer vaccine consisting of autologous cancer cells transfected with the human IL-2 gene. Hum Gene Ther 1996; 7:551-563.
31. Cascinelli N, Foa R, Parmiani G, et al.: Active immunization of metastatic melanoma patients with interleukin-4 transduced, allogeneic melanoma cells. A phase I-II study. Hum Gene Ther 1994; 5:1059-1064.
32. Morton DL, Foshag LJ, Hoon DS, et al.: Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 1992; 216:463-482.
33. Morton DL, Nizze A, Hoon D, et al.: Improved survival of advanced stage IV melanoma following active immunotherapy: correlation with immune response to melanoma vaccine [Abstract]. Proc Am Soc Clin Oncol 1993; 12:391.
34. Hsueh EC, Nizze A, Essner R, et al.: Adjuvant immunotherapy with polyvalent melanoma cell vaccine (PMCV) prolongs survival after complete resection of distant melanoma metastases [Abstract]. Proc Am Soc Clin Oncol 1997; 16:492.
35. Barth A, Hoon DS, Foshag LJ, et al.: Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response. Cancer Res 1994; 54:3342-3345.
36. Austin FC, Boon CW: Virus augmentation of the antigenicity of tumor cell extracts. Adv Cancer Res 1979; 30:301-345.
37. Wallack MK: Specific immunotherapy with vaccinia oncolysates. Cancer Immunol Immunother 1981; 12:1-4.
38. Wallack MK, Bash JA, Leftheriotis E, et al.: Positive relationship of clinical and serologic responses to vaccinia melanoma oncolysate. Arch Surg 1987; 122:1460-1463.
39. Wallack MK, Sivanandham M, Balch CM, et al.: A phase III randomized double-blind, multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma. Cancer 1995; 75:34-42.
40. Hersey P: Evaluation of vaccinia viral lysates as therapeutic vaccines in the treatment of melanoma. Ann N Y Acad Sci 1993; 690:167-177.
41. Hersey P: Active immunotherapy with viral lysates of micrometastases following surgical removal of high-risk melanoma. World J Surg 1992; 16:251-260.
42. Mitchell MS, Harel W, Kempf RA, et al.: Active specific immunotherapy of melanoma. J Clin Oncol 1992; 10:1158-1164.
43. Mitchell MS, Harel W, Kan-Mitchell J, et al.: Active specific immunotherapy of melanoma with allogeneic cell lysates. Rationale, results, and possible mechanisms of action. Ann NY Acad Sci 1993; 690:153-166.
44. Elliott GT, McLeod RA, Perez J, Von Eschen KB: Interim results of a phase II multicenter clinical trial evaluating the activity of a therapeutic allogeneic melanoma vaccine (theraccine) in the treatment of disseminated malignant melanoma. Semin Surg Oncol 1993; 9:264-272.
45. Mitchell MS, Von Eschen KB: Phase III trial of Melacine melanoma theraccine vs. combination chemotherapy in the treatment of stage IV melanoma [Abstract]. Proc Am Soc Clin Oncol 1997; 16:1778.
46. Mitchell MS, Jakowatz J, Harel W, et al.: Increased effectiveness of interferon alfa-2b following active specific immunotherapy for melanoma. J Clin Oncol 1994; 12:402-411.
47. Livingston PO, Ritter G, Srivastava P, et al.: Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside. Cancer Res 1989; 49:7045-7050.
48. Livingston PO, Natoli EJ, Calves MJ, et al.: Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Proc Natl Acad Sci USA 1987; 84:2911-2915.
49. Livingston PO, Wong GY, Adluri S, et al.: Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994; 12:1036-1044.
50. Kitamura K, Livingston PO, Fortunato SR, et al.: Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine. Proc Natl Acad Sci USA 1995; 92:2805-2809.
51. Hoon DS, Yuzuki D, Hayashida M, Morton DL: Melanoma patients immunized with melanoma cell vaccine induce antibody responses to recombinant MAGE-1 antigen. J Immunol 1995; 154:730-737.
52. Morioka N, Kikumoto Y, Hoon DS, et al.: A decapeptide (Gln-Asp-Leu-Thr-Met-Lys-Tyr-Gln-Ile-Phe) from human melanoma is recognized by CTL in melanoma patients. J Immunol 1994; 153:5650-5658.
53. Tsuchida T, Saxton RE, Morton DL, Irie RF: Gangliosides of human melanoma. J Natl Cancer Inst 1987; 78:45-54.
54. Ravindranath MH, Morton DL, Irie RF: An epitope common to gangliosides O-acetyl-GD3 and GD3 recognized by antibodies in melanoma patients after active specific immunotherapy. Cancer Res 1989; 49:3891-3897.
55. a are differentiation antigens immunogenic in human melanoma. Cancer 1997; 79:1686-1697.
56. Jones RC, Kelley MC, Gupta RK, et al.: Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: an immunologic survival model. Ann Surg Oncol 1996; 3:437-445.
57. Hsueh EC, Gupta RK, Qi K, et al.: TA90 immune complex predicts survival following surgery and adjuvant immunotherapy for stage IV melanoma. Cancer J Sci Am 1997; 3:364-370.
58. Gabrilovich DI, Ciernik IF, Carbone DP: Dendritic cells in antitumor immune responses. I: Defective antigen presentation in tumor-bearing hosts. Cell Immunol 1996; 170:101-110.
59. Hoon DS, Banez M, Okun E, et al.: Modulation of human melanoma cells by interleukin-4 and in combination with gamma-interferon or alpha-tumor necrosis factor. Cancer Res 1991; 51: 2002-2008.
60. Rosenberg SA, Packard BS, Aebersold PM, et al.: Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 1988; 319:1676-1680.
61. Golumbek PT, Azhari R, Jaffee EM: Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design. Cancer Res 1993; 53:5841-5844.
62. Zatloukal K, Schneeberger A, Berger M, et al.: Elicitation of a systemic and protective anti-melanoma immune response by an IL-2-based vaccine. J Immunol 1995; 154:3406-3419.
63. Porgador A, Gansbacher B, Bannerji R, et al.: Anti-metastatic vaccination of tumor-bearing mice with IL-2-gene-inserted tumor cells. Im J Cancer 1993; 53:471-477.
64. Moller AR, McBride WH, Dubinett SM, et al.: Transduction of human melanoma cell lines with human interleukin-7 gene using retroviral-mediated gene transfer: comparison of immunologic properties with interleukin-2. Blood 1993; 82:3686-3694.
65. Dranoff G, Jaffee E, Lazenby A, et al.: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90:3539-3543.
66. Steinman RM: Dendritic cells and immune-based therapies [Review]. Exp Hematol 1996; 24:859-862.
67. Steinman RM: The dendritic cell system and its role in immunogenicity [Review]. Annu Rev Immunol 1991; 9:271-296.
68. Morse MA, Zhou LJ, Tedder TF, et al.: Generation of dendritic cells in vitro from peripheral blood mononuclear cells with granulocyte-macrophage-colony-stimulating factor, interleukin-4, and tumor necrosis factor-α for use in cancer immunotherapy. Ann Surg 1997; 226:6-16.
69. Gabrilovich DI, Nadaf S, Corak J, et al.: Dendritic cells in antitumor immune responses. II: Dendritic cells grown from bone marrow precursors but not mature DC from tumor-bearing mice are effective antigen carriers in the therapy of established tumors. Cell Immunol 1996; 170:111-119.
70. Hsu FJ, Benike C, Fagnoni F, et al.: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med 1996; 2:52-8.
71. Plaksin D, Porgador A, Vadai E, et al.: Effective anti-metastatic melanoma vaccination with tumor cells transfected with MHC genes and/or infected with Newcastle disease virus (NDV). Int J Cancer 1994; 59-796-801.
72. Townsend SE, Su FW, Atherton JM, Allison JP: Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res 1994; 54:6477-6483.